



SITC 2025 Annual Meeting Schedule

Friday, Nov. 7–Sunday, Nov. 9

Welcome to our 40th Anniversary Annual Meeting. You can view the entire Annual Meeting schedule below.

[Pre-Conference Schedule](#)[Abstract Information](#)

- [Annual Meeting](#) [Friday, Nov. 7](#)
- [Annual Meeting](#) [Saturday, Nov. 8](#)
- [Annual Meeting](#) [Sunday, Nov. 9](#)

[Download Schedule PDF](#)

Friday, Nov. 7, 2025

40th Anniversary Annual Meeting | Gaylord National Resort and Convention Center | 7:45 a.m.–7 p.m. ET

Times and program schedules subject to change.

Session 100: Presidential Welcome

7:45–7:50 a.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Potomac Ballroom

View Full Session Schedule

7:45 a.m. Presidential Welcome

Session Description

Coming soon

Session 101: Awards Ceremony

7:50–8:20 a.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Potomac Ballroom

Chair: TBA

View Full Session Schedule

7:50 a.m. **Coming Soon**
TBA

Session Description

Coming soon

Session 102: Keynote Address

8:20–9:10 a.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Potomac Ballroom

Chair: TBA

View Full Session Schedule

8:20 a.m. **Introduction**
James Gulley, MD, PhD, FACP – *National Cancer Institute*

8:25 a.m. **Targeting the Microbiome to Promote Health and End Cancer**
Jennifer A. Wargo, MD, MMSc – *The University of Texas MD Anderson Cancer Center*

Session Description

Coming Soon

Break

9:10–9:40 a.m. ET

Session 103: Thomas Waldmann Memorial Plenary Session: Untapped Opportunities in Immuno-oncology

9:40–11:30 a.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Potomac Ballroom

Co-Chairs: Lisa Coussens, PhD, FAIO – *Oregon Health & Science University* & Christine Moussion, PhD – *Genentech*

View Full Session Schedule

- | | |
|-------------------|--|
| 9:40 a.m. | Introduction
Lisa Coussens, PhD – <i>Oregon Health & Science University</i> |
| 9:50 a.m. | High-Level Overview of Neuro-Immunology
Ulrich von Andrian, MD, PhD – <i>Harvard University</i> |
| 10:10 a.m. | Neuro-Immunology, Metastasis in Neuroendocrine Tumors
Christine Moussion, PhD – <i>Genentech</i> |
| 10:30 a.m. | Abstract
TBA |
| 10:40 a.m. | Serotonin Reuptake Inhibitor and Response to Immunotherapy in Cancer
Lili Yang, PhD - <i>University of California, Los Angeles</i> |
| 11:00 a.m. | Abstract
TBA |
| 11:10 a.m. | Neuro-Tumor Communication as Mechanism of Resistance
Sohail Tavazoie, MD, PhD – <i>Rockefeller University</i> |

Session Description

Neuroimmune communication in cancer pathology and therapeutic responses remains an area that is poorly understood. This session aims to bridge the central nervous system and the periphery by focusing on neuro-immune communication in solid tumors highlighting it as an untapped opportunity for future therapeutic approaches. We will explore neuron-intrinsic, tumor intrinsic, and drug-associated neuromodulation of the tumor microenvironment and immune responses related to cancer immunotherapy in both preclinical and translational research settings.

Session 104: Clinical Oral Abstract Session

11:30 a.m.–12:15 p.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Potomac Ballroom

Chair: TBD

View Full Session Schedule

11:45 a.m. **Coming Soon**
TBA

Session Description

Coming Soon

Exhibits and Poster Viewing

12:15–1:45 p.m. ET

Gaylord National Resort and Convention Center - Lower Level Atrium - Prince George's ABC

Concurrent Session 105a: Rapid Oral Abstract Session - Basic

12:30–1:30 p.m. ET | Gaylord National Resort and Convention Center - Maryland Ballroom AB

Co-Chairs: Aitziber Buque Martinez, PhD – *Fox Chase Cancer Center* & Kristin DePeaux, PhD – *Princeton University*

View Full Session Schedule

12:30 p.m. **Coming Soon**
TBA

Session Description

Coming Soon

Concurrent Session 105b: Rapid Oral Abstract Session - Clinical

12:30–1:30 p.m. ET | Gaylord National Resort and Convention Center- Maryland Ballroom CD

Co-Chairs: Allison Betof Warner, MD, PhD – *Stanford Medicine* & Adam Grippin, MD, PhD – *MD Anderson Cancer Center*

View Full Session Schedule

12:30 p.m. Coming Soon
TBA

Session Description

Coming Soon

Concurrent Session 106a: Considerations for Incorporating Biomarkers in Perioperative/Neoadjuvant Therapy

1:45–3:25 p.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Potomac Ballroom

Co-Chairs: Sonia Cohen, MD, PhD – *Massachusetts General Hospital* & Thomas Marron, MD, PhD – *Mount Sinai*

View Full Session Schedule

- 1:45 p.m.

Recent Advances in Neoadjuvant Therapies
Sonia Cohen, MD, PhD – *Massachusetts General Hospital*
- 2:00 p.m.

Harnessing the Neoadjuvant Space: A Window-of-Opportunity to See How Our Novel Drugs Actually Work
Thomas Marron, MD, PhD – *Mount Sinai*
- 2:15 p.m.

Incorporating Surrogate Endpoints into Clinical Trials
Janis M. Taube, MD, MSc – *Johns Hopkins School of Medicine*
- 2:30 p.m.

Regulatory Issues and Surrogate Endpoints
Harpreet Singh, MD – *Precision for Medicine*
- 2:45 p.m.

Abstract
TBA
- 2:55 p.m.

Abstract
TBA
- 3:05 p.m.

Abstract
TBA
- 3:15 p.m.

Panel Discussion/Q&A

Session Description

This session will explore the current use of perioperative immunotherapy, emerging biomarkers to guide treatment decision making, and the scientific potential of the neoadjuvant space to elucidate mechanisms of action of novel immunotherapies.

Concurrent Session 106b: Microbiota and IO: Mode of Action and Clinical Relevance

1:45–3:25 p.m. ET | Gaylord National Resort and Convention Center - Ballroom Level-Maryland Ballroom AB

Co-Chairs: Bertrand Routy, MD, PhD – *University of Montreal (CHUM)* & Laurence Zitvogel, MD, PhD, FAIO – *Gustave Roussy*

View Full Session Schedule

- | | |
|------------------|---|
| 1:45 p.m. | From FMT to Second Generation Microbiome Interventions to Increase Cancer Immunotherapy Efficacy
Bertrand Routy, MD, PhD – <i>University of Montreal (CHUM)</i> |
| 2:00 p.m. | Microbial Bile Acids: Chemistry and Clinical Applications
Robert A. Quinn, PhD – <i>Michigan State University</i> |
| 2:15 p.m. | Live Biotherapeutic SER-155 for in Hematopoietic Cell Transplantation
Jonathan U. Peled, MD, PhD – <i>Memorial Sloan Kettering Cancer Center</i> |
| 2:30 p.m. | Subclinical Cholestasis, Gut Microbiota and Cancer Immunosurveillance
Laurence Zitvogel, MD, PhD, FAIO – <i>Gustave Roussy</i> |
| 2:45 p.m. | Abstract
TBA |
| 2:55 p.m. | Abstract
TBA |
| 3:05 p.m. | Q&A/Conclusion
TBA |

Session Description

Immunotherapies, including immune checkpoint inhibitors, hematopoietic stem cell transplantation, and CAR-T cell therapies, depend heavily on a healthy gut barrier and a diverse gut microbiome for optimal efficacy. Dysbiosis, or an imbalance in gut microbial composition and function, can diminish immunotherapy responses by altering immune cell activation, trafficking and metabolic output. New diagnosis tools have been reported to assess gut dysbiosis. Key microbial metabolites such as short-chain fatty acids and modified bile acids

shape host immunity and influence cancer immunosurveillance in some tissues. Emerging strategies to restore a balanced microbiome and boost therapy efficacy include dietary interventions, prebiotics, live biotherapeutics, and faecal microbiota transplantation. Four speakers will cover these chapters of defining gut dysbiosis, analyzing its functional consequences on homeostasis and cancer immunity and proposing compensatory microbiota-centered interventions.

Concurrent Session 106c: Immunoprevention, Immune Interception

1:45–3:25 p.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Maryland Ballroom CD

Co-Chairs: Robert Samstein, MD, PhD – *Icahn School of Medicine at Mount Sinai Tisch Cancer Institute* & Jianjun Zhang, MD, PhD – *The University of Texas MD Anderson Cancer Center*

View Full Session Schedule

1:45 p.m.	Introduction Co-Chair
1:51 p.m.	Clinical Data in Lung Cancer Robert Keith, MD – <i>University of Colorado</i>
2:13 p.m.	Reprogramming the Immune Microenvironment to Intercept Lung Adenocarcinoma Precancer Jianjun Zhang, MD, PhD – <i>The University of Texas MD Anderson Cancer Center</i>
2:35 p.m.	MUC1 in Lung Cancer, Breast, Colon, Pancreatic Olivera Finn, PhD – <i>University of Pittsburgh</i>
2:57 p.m.	Cancer Immune Surveillance and Prevention Shadmehr Demehri, MD, PhD – <i>Massachusetts General Hospital</i>
3:19 p.m.	Conclusion Co-Chair

Session Description

Cancer remains a major global health challenge, with poor outcomes in advanced stages highlighting the urgent need for earlier and more effective interventions. Immune evasion is a hallmark of cancer across all types, and strategies that reprogram host immunity—either to prevent cancer (immune prevention) or to halt the progression of precancers (immune interception)—offer promising avenues to reduce cancer incidence,

morbidity, and mortality. Immunoprevention has already achieved remarkable success in virus-associated cancers, such as those caused by hepatitis B virus and human papillomavirus, demonstrating its potential. In recent years, pioneering research in non-virus-related premalignancies—such as lung, colorectal, and gynecologic cancers—has laid the groundwork for broader application of immune-based prevention strategies. Encouragingly, early clinical trial data are emerging in high risk populations, including those involving vaccines, immune checkpoint inhibitors, and agents targeting inflammasome pathways. This session will highlight some of these ongoing studies with the ultimate goal of shedding light on the future of immune-based cancer prevention and interception, with the potential to transform cancer control across multiple tumor types.

Concurrent Session 106d: Regulatory Issues with a Focus on Pediatric Cancers and Early Onset Cancers

1:45–3:25 p.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Cherry Blossom Ballroom

Co-Chairs: Christian Capitini, MD – *University of Wisconsin-Madison* & Bambi Grilley, RPh, RAC, CIP, CCRC&P – *Baylor College of Medicine*

View Full Session Schedule

- | | |
|------------------|---|
| 1:45 p.m. | Introduction
Session Co-Chair |
| 1:50 p.m. | Regulatory Aspects of Genetically Engineered Immune Effector Cells; Differences in Children and Adults
Andras Heczey, MD – <i>Seattle Children's Research Institute</i> |
| 2:10 p.m. | Regulatory Issues for Non-Cellular Therapies
Raphaël Rousseau, MD, PhD – <i>Pheast Therapeutics</i> |
| 2:30 p.m. | CAR Studies for Neuroblastoma
Rosandra N. Kaplan, MD – <i>National Cancer Institute</i> |
| 2:50 p.m. | Panel Discussion
TBA |
| 3:20 p.m. | Conclusion
Session Co-Chair |

Session Description

This session will inform attendees on the unique regulatory aspects of developing immunotherapies, including both adoptive cell therapies and immune checkpoint inhibitors, for childhood cancers drawing on experiences from academia, industry and government. Differences in the tumor immune microenvironment in pediatric and adult cancers will be reviewed. Innate (CAR-NKT) and adaptive (CAR-T) immune cell biology, manufacturing and monitoring will also be discussed.

Concurrent Session 106e: Oral Abstract Session

1:45–3:25 p.m. ET | Gaylord National Resort and Convention Center - National Harbor Conference Rooms - National Harbor 2-3

Co-Chair: Alexander M.M. Eggermont, MD, PhD - *Princess Máxima Center, UMC Utrecht and Comprehensive Cancer Center München*

View Full Session Schedule

1:45 p.m. **Introduction**
TBA

Session Description

Coming Soon

Break

3:25–3:55 p.m. ET

Concurrent Session 107a: Age-Related Changes in the Tumor Immune Microenvironment: Biological Implications and Clinical Significance

3:55–5:35 p.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Cherry Blossom Ballroom

Co-Chairs: Derek A. Wainwright, PhD – *Loyola University Chicago* & Ashani Weeraratna, PhD – *Johns Hopkins University*

View Full Session Schedule

3:55 p.m. **Metabolic Regulation of Immune Aging in the Tumor Microenvironment**
Sheila A. Stewart, PhD – *Washington University*

4:15 p.m. **Age-Dependent Alterations in Immune Cell Function and Implications for Tumor Dormancy**
Mitchell Fane, PhD – *Fox Chase Cancer Center*

4:35 p.m. **Aging Stroma and Melanoma Immunotherapy Response: Mechanisms and Targets**
Amaya Viros, MD, PhD – *Cancer Research UK Manchester Institute*

4:55 p.m. **Neuro-Immune Interactions in Aging and Cancer: Implications for Immunotherapy**
Derek Wainwright, PhD – *Loyola University Chicago Stritch School of Medicine*

5:15 p.m. **Abstract**
TBA

5:25 p.m. **Abstract**
TBA

Session Description

With a global population of older adults that's projected to double by 2050, combined with the significantly increased cancer incidence in patients who are >60 years of age, it's critical to understand how age affects tumor-immune cell interactions to achieve maximum immunotherapeutic efficacy. This session will highlight emerging research and promising therapeutic strategies that address challenges in cancer immunology across the lifespan.

Concurrent Session 107b: Modulation of Anti-Tumor Immunity by Nerves and Neurotransmitters

3:55–5:35 p.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Maryland Ballroom AB

Co-Chairs: Kylynda Bauer, PhD – *NIH-National Cancer Institute* & Benoit Van den Eynde, MD, PhD – *University of Oxford*

View Full Session Schedule

- | | |
|------------------|--|
| 3:55 p.m. | Neuroimmune Driver of Cancer Inflammation
Sebastien Talbot, PhD— <i>Queen's University</i> |
| 4:15 p.m. | Adrenergic Control of Tumor Immunity
Jingjing Zhu, PhD - <i>Ludwig Institute for Cancer Research</i> |
| 4:35 p.m. | Clinical Perspective of Neuroimmunology
Moran Amit, MD, PhD – <i>The University of Texas MD Anderson Cancer Center</i> |
| 4:55 p.m. | Microbiome-Neuroimmune Interactions of Liver Cancer
Kylynda Bauer, PhD – <i>National Cancer Institute</i> |
| 5:15 p.m. | Abstract
TBA |
| 5:25 p.m. | Abstract
TBA |

Session Description

Nerves recently emerged as a critical component of the tumor microenvironment. The immune system integrates vast non-immune signals, sensing and responding to nerves and neurotransmitters. Nerves elicit pro- and anti-tumor immunity in context-specific malignancies. Precise neuroimmune interactions in cancer pathology and therapeutic response remain largely unstudied. Beyond local tumor outcomes, neuroimmune crosstalk regulates external signals from the gut microbiome and immunotherapies. This session highlights

work identifying key neuroimmune receptors, signaling arcs, and clinical discoveries in cancer neuroimmunity. Immunosuppression is a key challenge in cancer research. Multidisciplinary, translational research is required to promote anti-tumor immunity and immunotherapy efficacy via neuroimmune modulation.

Concurrent Session 107c: Immune Regulatory Subsets in Tumors

3:55–5:35 p.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Maryland Ballroom CD

Co-Chairs: Jennifer L. Guerriero, PhD – *Brigham and Women's Hospital* & Sergio Quezada, PhD – *University College London*

View Full Session Schedule

3:55 p.m.	Introduction Co-Chair
4 p.m.	Regulatory T Cells & Myeloid Aurélien Marabelle, MD, PhD – <i>Gustave Roussy</i>
4:20 p.m.	Myeloid Florent Ginhoux, PhD – <i>Gustave Roussy</i>
4:40 p.m.	TLS/B Cell Tullia Bruno, PhD – <i>University of Pittsburgh</i>
5 p.m.	Abstract TBA
5:15 p.m.	Abstract TBA
5:30 p.m.	Conclusion Co-Chair

Session Description

The tumor microenvironment (TME) is a highly complex and dynamic ecosystem, where diverse immune cell subsets interact to regulate tumor progression, immune surveillance, and response to therapy. Among these, regulatory immune populations—including Regulatory T cells, myeloid cells, and B cells—can play multifaceted roles that can either support or suppress anti-tumor immunity. A comprehensive understanding of each subset's function and interplay is essential for the rational design of effective immunotherapies.

This session will explore recent advances in our understanding of regulatory immune subsets in tumors, focusing on their phenotypic diversity, dynamics, and functional crosstalk within the TME through progression and therapy. By examining the complexity of these populations individually and in context, the session will highlight the need for integrative approaches to identify therapeutic targets and improve patient outcomes.

Concurrent Session 107d: The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics

3:55–5:35 p.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - Potomac Ballroom

Co-Chairs: Kristen Hege, MD – *Board Member, Mersana, Adaptimmune, Kelonia, KSQ and EvolveImmune* & Zhen Su, MD, MBA – *Marengo Therapeutics*

View Full Session Schedule

3:55 p.m.	Introduction Zhen Su, MD, MBA – <i>Marengo Therapeutics</i>
4 p.m.	CAN -2409 Development in Prostate Cancer Paul Peter Tak, MD, PhD – <i>Candel Therapeutics</i>
4:15 p.m.	Cellular Therapy Beyond Oncology Ashley Koegel, MD – <i>Bristol Myers Squibb</i>
4:30 p.m.	PD-1/VEGF Bispecific Allen S. Yang, MD, PhD – <i>Summit Therapeutics</i>
4:45 p.m.	Abstract TBA
4:55 p.m.	Abstract TBA
5:05 p.m.	Panel Discussion Daina Graybosch, PhD – <i>Leerink Partners</i> Kristen Hege, MD – <i>Board Member, Mersana, Adaptimmune, Kelonia, KSQ and EvolveImmune</i> Ashley Koegel, MD – <i>Bristol Myers Squibb</i> Brad Loncar, BBA – <i>BiotechTV</i> Zhen Su, MD, MBA – <i>Marengo Therapeutics</i> Paul Peter Tak, MD, PhD – <i>Candel Therapeutics</i> Allen S. Yang, MD, PhD – <i>Summit Therapeutics</i>
5:30 p.m.	Conclusion Kristen Hege, MD – <i>Board Member, Mersana, Adaptimmune, Kelonia and EvolveImmune</i>

Session Description

Immunotherapy has dramatically changed the treatment of many different cancers including broad activity of immune checkpoint blockers against both solid and hematologic tumors as well as deep and durable responses with T cell based therapies in blood cancers and more recently in limited solid tumor indications. Looking forward, next generation approaches across cancer immunotherapy platforms are showing great promise. This includes exciting results with bispecific antibodies target immune checkpoints and other immune modulatory pathways (eg, PD-1 + VEGF), T cell engagers, engineered oncolytic viral therapies, and movement of B-cell depleting chimeric antigen receptor (CAR) T cells into autoimmune diseases. This session will cover recent data from these next gen approaches and include a panel discussion on the state of the cancer "and beyond" immunotherapy field including both opportunities and obstacles for developing the next wave of breakthrough therapeutics.

Concurrent Session 107e: Oral Abstract Session 2

3:55–5:35 p.m. ET | Gaylord National Resort and Convention Center - Ballroom Level - National Harbor 2-3

Co-Chairs: TBA

View Full Session Schedule

3:50 p.m. **Coming Soon**
TBD

Session Description

Coming Soon

Exhibits and Poster Reception

5:35–7 p.m. ET

**Gaylord National Resort and Convention Center - Lower Level Atrium - Prince George's
ABC**